 What the decision handed down Thursday by the Patent Trial and Appeal Board could mean for Moderna ticker: MRNA isnt yet clear, but the stock fell 9.5 on Thursday, and was down another 5 Friday in premarket trading. In a statement Friday afternoon, Moderna said that the technology used in its Covid-19 vaccine isnt covered by the patent its suit had been brought to challenge. Moderna brought the case in January of 2019 against ABUS ABUS, a very small biotech, arguing that its patent for the technology used to deliver messenger RNA to a patients cells was unpatentable. 